CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity.

Product information

CAS Number: 154554-41-3

Molecular Weight: 283.25

Formula: C16H10FNO3

Chemical Name: 6-(2-fluorophenyl)-2H,5H,8H-[1,3]dioxolo[4,5-g]quinolin-8-one

Smiles: O=C1C=C(NC2=CC3OCOC=3C=C21)C1=CC=CC=C1F

InChiKey: ZMYDAPJHGNEFGQ-UHFFFAOYSA-N

InChi: InChI=1S/C16H10FNO3/c17-11-4-2-1-3-9(11)12-6-14(19)10-5-15-16(21-8-20-15)7-13(10)18-12/h1-7H,8H2,(H,18,19)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

CHM-1 (0-100μM; 24 hours) induces significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells (IC50 = 0.75 μM). CHM-1 (0-10 μM; 24 hours) significantly increases the binding of cyclin B1 to Cdc2 in HA22T cells.

In Vivo:

CHM-1 (10 mg/kg; I.p.) induces a dose-dependent inhibition of HA22T tumor growth.

Products are for research use only. Not for human use.